Vericel Strategy and Business Model

Executive Overview

Vericel is a U.S. advanced-therapies company focused on two narrow but defensible clinical markets: sports medicine cartilage repair and severe burn care. Headquartered in Cambridge, Massachusetts, the company traces its roots to Aastrom Biosciences, founded in 1989, and was strategically reshaped by its 2014 acquisition of Sanofi’s cell therapy and regenerative medicine business. Vericel’s commercial portfolio now centers on MACI, an autologous cell therapy for knee cartilage defects; Epicel, a permanent skin replacement for patients with extensive burns; and NexoBrid, a biologic used for eschar removal in adult thermal-burn patients. Vericel reported approximately $238.6 million of revenue in FY2024, with MACI contributing the majority of sales. The company’s strategy is not broad drug discovery. Instead, it is to own specialty treatment pathways where manufacturing know-how, clinical evidence, reimbursement support, and tightly coordinated logistics create barriers to entry. Its commercial footprint is still primarily U.S.-based, which simplifies execution but concentrates payer and regulatory exposure. Growth depends mainly on deeper MACI penetration, wider burn-center adoption of NexoBrid and Epicel, and disciplined scaling of a high-touch cell-therapy operating model.

Vericel at a Glance

Logo
Common name	Vericel
Full legal name	Vericel Corporation
Headquarters	Cambridge, Massachusetts, United States
Ownership	Public company; no controlling shareholder disclosed in recent SEC filings
Ticker	VCEL
Exchange	NASDAQ
Market Cap	$2.06B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1989 as Aastrom Biosciences; acquired Sanofi’s cell therapy business in 2014; renamed Vericel in 2015; MACI received FDA approval in 2016; NexoBrid received FDA approval in 2022; MACI arthroscopic delivery was approved in 2025
Industry or industries	Biotechnology; regenerative medicine; advanced cell therapy; sports medicine; severe burn care
Key products or services	MACI, Epicel, NexoBrid; specialty reimbursement support; case coordination; cell-therapy manufacturing and delivery
Geographic footprint	Commercial operations primarily in the United States; North American rights for NexoBrid; manufacturing and corporate concentration in Massachusetts
Business segments as officially reported	One reportable segment
Company website	https://www.vericel.com

1. What Is the Strategy of Vericel?

Vericel’s public materials point to a focused specialty-biotech strategy: concentrate on advanced therapies where clinical differentiation, manufacturing complexity, and specialized commercialization make the market attractive even if the addressable population is narrower than in mass-market pharmaceuticals. Using the Playing to Win framework, the strategy can be summarized as follows.

1. 1a. What is the winning aspiration of Vericel?

   Vericel’s winning aspiration is to be a leading advanced-therapies company in sports medicine and severe burn care by making its products the preferred treatment options in the clinical niches it serves. Public statements and investor materials emphasize restoring damaged cartilage, improving outcomes in catastrophic burns, and building durable growth from a small number of differentiated products rather than chasing broad therapeutic diversification. Quantitatively, management has highlighted the large underpenetrated U.S. cartilage-repair opportunity for MACI and the remaining adoption runway for burn-center products. In practical terms, winning means expanding MACI toward broader standard-of-care status in knee cartilage repair while building a more complete burn franchise around Epicel and NexoBrid.

2. 1b. Where does Vericel play?

   Vericel plays in a deliberately narrow competitive field. It focuses on the United States, on specialist providers, and on treatment settings where clinical training and logistics matter. In sports medicine, that means orthopedic and sports-medicine surgeons treating cartilage defects of the knee. In burn care, it means specialized burn centers and hospitals treating severe thermal injuries. The company does not try to compete broadly across orthopedics, wound care, or general biologics. It concentrates on high-acuity, procedure-linked therapies where a differentiated product can be supported by a direct field force, reimbursement assistance, and specialized manufacturing.

3. 1c. How does Vericel plan to win?

   Vericel plans to win through a combination of clinical differentiation and operational execution. MACI is not a commodity implant; it is a patient-specific autologous therapy with a distinct evidence base and a defined surgical workflow. Epicel serves a rare and urgent use case where alternatives are limited. NexoBrid adds a biologic debridement option that can deepen Vericel’s relevance in burn centers. The company’s value proposition is therefore not just the molecule or graft itself. It also includes surgeon education, case coordination, reimbursement support, and reliable product delivery. That integrated model makes Vericel harder to displace than a company selling a simpler off-the-shelf product.

4. 1d. What capabilities must Vericel have in place?

   The essential capabilities are highly specific. Vericel needs current Good Manufacturing Practice (cGMP) cell-therapy manufacturing, chain-of-identity and scheduling discipline for autologous products, strong quality and regulatory systems, and a specialized commercial organization that can educate surgeons and hospitals rather than just promote a brand. It also needs reimbursement expertise because hospital adoption depends on coding, payment, and patient-access workflows. For burn care, account relationships at specialized centers are critical. For MACI, surgeon training and confidence in procedure selection are central to growth.

5. 1e. What management systems does Vericel require?

   Vericel needs management systems that reinforce precision and reliability. That includes quality-control systems, lot and patient tracking, manufacturing-capacity planning, adverse-event monitoring, and cross-functional coordination between sales, reimbursement, operations, and medical affairs. It also requires commercial metrics that are more account-based than mass-market, such as surgeon activation, procedure volume by account, burn-center penetration, formulary progress, and case completion. Because the portfolio is concentrated, capital-allocation discipline is also important: management must continuously balance growth investments in sales and clinical development against the need to preserve profitability and service quality.

2. What Are the Current Strategic Initiatives of Vericel?

Vericel’s recent filings, investor materials, and product announcements point to a small set of highly specific strategic initiatives.

• Expand MACI penetration in knee cartilage repair. MACI remains Vericel’s primary growth engine. The company has continued to invest in surgeon education, account penetration, reimbursement support, and patient-awareness efforts to drive broader use in the existing cartilage-repair market.
• Commercialize the newly approved arthroscopic delivery option for MACI. In January 2025, Vericel announced FDA approval of MACI for arthroscopic delivery. Strategically, this matters because it can reduce procedural burden, align the product more closely with familiar arthroscopic workflows, and potentially expand the addressable surgeon base and site-of-care flexibility.
• Build a broader burn-care franchise around Epicel and NexoBrid. Vericel has been working to expand NexoBrid adoption in U.S. burn centers while continuing Epicel growth in severe burns. The logic is clear: once Vericel is embedded in a burn center, a broader product portfolio can strengthen account relevance and clinical relationships.
• Pursue lifecycle management and label expansion. Publicly discussed development work has included pediatric expansion efforts for NexoBrid with partner MediWound and additional MACI administration and use-case improvements. These initiatives should be treated as pipeline or regulatory opportunities until approvals are secured.
• Protect manufacturing reliability and service levels. Because MACI and Epicel are patient-specific, operational execution is itself a strategic initiative. Vericel continues to emphasize manufacturing readiness, quality systems, and logistics coordination to support growing volume without undermining service.
• Balance growth spending with profitability. As Vericel has become more profitable, management has emphasized disciplined commercial and clinical investment rather than growth at any cost. That is particularly important for a company with a narrow portfolio and high customer-service expectations.

3. What Is the Business Model of Vericel?

What customers buy. Vericel sells specialty advanced-therapy products used in procedure-based care. Hospitals, ambulatory surgery centers, and burn centers are the direct economic customers, while surgeons are the primary clinical decision-makers. What buyers are really purchasing is not just a physical product, but a full treatment pathway supported by manufacturing, scheduling, reimbursement, and case coordination.

Recurring versus one-time revenue. Vericel’s products are generally one-time therapies at the patient level. A patient receives MACI, Epicel, or NexoBrid for a specific clinical event, not on a subscription basis. But the model is still repeat-driven at the account level because surgeons and hospitals continue to treat new patients over time. That makes account retention, surgeon activation, and site penetration more important than pure unit repeat per patient.

How pricing power works. Vericel appears to have meaningful pricing support because its products are differentiated, clinically specialized, and in some cases face limited direct alternatives. That said, pricing power is not unlimited. Real-world realization depends on hospital economics, payer coverage, prior authorization, and whether the clinical pathway is easy enough for providers to adopt.

Why the business mix matters. MACI is the economic center of gravity. It appears to drive most revenue and likely much of the company’s operating leverage. Burn-care products diversify the business and strengthen Vericel’s specialty identity, but burn demand is inherently more episodic. A mix shift toward larger MACI volume generally should help absorption of fixed infrastructure, while successful NexoBrid adoption can improve the strategic depth of the burn franchise.

What drives margins and cash generation. Gross margin is driven by product mix, manufacturing yields, utilization of specialized facilities, and the cost profile of patient-specific production. Operating margin depends heavily on sales-force productivity and how efficiently Vericel spreads quality, manufacturing, and commercial overhead across volume growth. Cash generation improves when revenue rises faster than the fixed infrastructure required to support a specialty cell-therapy platform. This is a product-sales business, not a royalty or subscription model.

4. What Products and/or Services Does Vericel Sell?

Vericel is essentially a three-product commercial company, with each product tied to a specialized clinical pathway.

• MACI. Vericel’s flagship product, MACI is an autologous cultured chondrocyte implant on a porcine collagen membrane used to repair symptomatic cartilage defects of the knee. It is the company’s largest product and the clearest driver of revenue, commercial investment, and long-term growth strategy.
• Epicel. Epicel is a permanent skin-replacement therapy for patients with deep dermal or full-thickness burns covering a large percentage of total body surface area. It serves a highly specialized and urgent market, historically under a Humanitarian Device Exemption framework.
• NexoBrid. NexoBrid is a biologic for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. Vericel holds North American rights and has been building its commercial position in U.S. burn centers. Strategically, NexoBrid broadens the company’s burn-care relevance beyond skin replacement alone.
• Associated support services. Vericel also provides case coordination, order management, reimbursement support, and clinical education around these products. These services are not separate revenue lines in the way a software module would be, but they are integral to adoption and execution.

Legacy products matter mainly historically. Carticel, the earlier autologous cartilage-repair product, was strategically important in Vericel’s evolution but has been superseded by MACI.

5. What Are the Key Competitors or Peers of Vericel?

Vericel has relatively few exact product-for-product competitors. In many cases, it competes against alternative procedures, grafting methods, or hospital treatment protocols rather than a single directly equivalent branded therapy.

Just as important as named companies are non-corporate substitutes: microfracture, osteochondral autograft or allograft procedures, traditional excision and grafting approaches in burns, and other clinician-selected treatment pathways. For Vericel, changing physician behavior is often as important as beating a branded rival.

6. What Is the Marketing Strategy of Vericel?

Vericel’s marketing approach is best understood as specialty clinical marketing, not mass-market pharmaceutical promotion. The company sells into narrow physician audiences and high-value treatment settings, so awareness alone is not enough. Marketing has to support procedure adoption, reimbursement confidence, and account activation.

For MACI, the marketing strategy appears to combine brand awareness, surgeon education, patient-awareness efforts, and practical support around the treatment journey. Because MACI requires biopsy, manufacturing, implantation, and rehabilitation, the real marketing challenge is reducing friction across the pathway. The January 2025 arthroscopic delivery approval gives Vericel a meaningful new message for surgeons who may have seen MACI as procedurally burdensome.

For Epicel and NexoBrid, marketing is more account-based and clinically focused. Burn centers are specialized, so formulary access, protocol adoption, medical education, and peer-to-peer clinical support matter more than broad brand advertising. In that sense, marketing is an enabling capability rather than the sole differentiator. Clinical evidence, specialist trust, and operational reliability do more of the strategic work.

7. What Are the Key Customer Segments of Vericel?

• Orthopedic and sports-medicine surgeons. These clinicians are the key decision-makers for MACI. Their comfort with diagnosis, patient selection, procedure workflow, and rehabilitation protocol strongly influences demand.
• Hospitals and ambulatory surgery centers. These are the economic buyers for MACI procedures. Their reimbursement workflows, operating-room economics, and administrative support affect adoption.
• Burn surgeons and burn centers. These are the core customers for Epicel and NexoBrid. The burn market is narrower and more concentrated than the sports-medicine market, making each account strategically important.
• Payers and reimbursement stakeholders. Vericel does not sell directly to insurers in the usual sense, but payer coverage and prior-authorization processes materially influence access. In practice, they are a critical stakeholder group.
• Patients and referral networks. Particularly for MACI, patient awareness and referral flow matter because the procedure is elective and pathway-driven rather than emergency-only.

Overall, Vericel is not highly diversified by end market. It depends heavily on orthopedic cartilage repair for scale and on a relatively small number of specialized burn accounts for its burn franchise.

8. What Is the Sales Model of Vericel?

Vericel uses a direct specialty sales model. It does not rely primarily on a broad distributor network or retail channels. That fits the nature of its products, which require clinician training, scheduling, and reimbursement support.

• MACI go-to-market model. Direct field representatives call on orthopedic and sports-medicine surgeons, hospitals, and surgery centers. The sale is consultative: it involves clinical education, account onboarding, case coordination, and reimbursement assistance, not just price negotiation.
• Burn franchise go-to-market model. Epicel and NexoBrid are sold through a focused account-based model into specialized burn centers and hospitals. Adoption depends on physician champions, pharmacy and therapeutics review, treatment protocols, and product availability in urgent settings.
• Channel implications. This direct model gives Vericel strong customer intimacy and better insight into barriers to adoption, but it also creates a relatively high fixed commercial cost base. Growth therefore depends on increasing productivity per account and per representative, not simply shipping more units through distribution.

This channel structure also creates clear consultant opportunities in territory design, CRM optimization, reimbursement workflow redesign, and burn-center account prioritization.

9. In What Geographies Does Vericel Operate?

Vericel’s operating footprint is concentrated primarily in the United States. Its commercial revenue base is overwhelmingly U.S.-focused, and its customer relationships are centered on U.S. orthopedic practices, hospitals, and burn centers. That concentration reduces foreign-exchange complexity and international commercial overhead, but it also means the company is highly exposed to U.S. reimbursement, regulation, and provider adoption patterns.

Operationally, Vericel’s core manufacturing and corporate presence is concentrated in Massachusetts, particularly Cambridge. The company also has North American rights to NexoBrid, which gives it a broader territorial scope on paper than its current revenue base. In practice, however, Vericel still looks like a U.S.-specialty commercial company more than a geographically diversified global biotech.

10. Who Are the Owners of Vericel?

Vericel is a publicly traded company. Based on recent proxy and SEC ownership disclosures in 2025, the shareholder base appears to be primarily institutional, and no single shareholder appears to have a controlling stake. Large holders disclosed in recent filings have included major asset managers such as BlackRock, The Vanguard Group, and other healthcare-focused institutional investors. As with most public companies, these ownership percentages can change over time.

11. How Is Vericel Organized?

Officially, Vericel reports one reportable segment. That is important because it means investors should not assume the company is managed or capitalized as a set of fully separate divisions with standalone reporting.

Practically, though, the business is easiest to understand through two commercial franchises:

• Sports medicine, centered on MACI
• Severe burn care, centered on Epicel and NexoBrid

Supporting those franchises are centralized functions such as manufacturing, quality, regulatory affairs, medical affairs, reimbursement, and corporate administration. This structure makes sense for a focused biotech: commercial specialization sits close to the customer, while regulated operations and infrastructure are shared across the portfolio.

12. How Does Vericel Operate?

Vericel’s day-to-day operations are built around precision execution rather than mass production.

1. For MACI, a physician takes a cartilage biopsy from the patient, the sample is shipped to Vericel, chondrocytes are expanded and prepared on the collagen membrane in a controlled manufacturing environment, and the finished implant is then delivered back for the scheduled procedure.
2. For Epicel, a small biopsy from a burn patient is used to grow cultured epithelial autografts that are then returned for use in urgent severe-burn treatment. Timing and service reliability are especially important because the clinical need can be acute.
3. For NexoBrid, the operating model is more like a specialty biologic launch: supply is sourced through the partner structure, burn centers must adopt the product into protocol, and Vericel supports commercial access and account execution.

The major operational complexities are predictable but material: sterile manufacturing, chain-of-identity control, case scheduling, surgical cancellations or delays, specialized shipping, reimbursement coordination, and regulatory compliance. In Vericel’s business, operations are not just back office. They are part of the value proposition.

13. What Are the Growth Opportunities for Vericel?

• Deeper MACI penetration in the existing knee cartilage market. This is the largest visible opportunity. Management has repeatedly framed MACI as underpenetrated relative to the number of cartilage-repair patients treated annually.
• MACI arthroscopic delivery. The January 2025 approval could improve surgeon adoption and broaden procedural fit. If it lowers friction meaningfully, it may become one of the most important growth catalysts in the company’s current portfolio.
• Broader burn-center adoption of NexoBrid. NexoBrid is still earlier in its U.S. commercialization curve than MACI. More formulary wins, protocol adoption, and physician familiarity could drive growth from a relatively low base.
• Cross-franchise depth in burn care. Epicel and NexoBrid can strengthen Vericel’s position with the same burn-center customer base. That can improve account productivity and customer stickiness.
• Label expansion and lifecycle management. Pediatric expansion for NexoBrid and further improvements around MACI use or delivery represent plausible growth levers if approved.
• Selective business development. Vericel is not a broad pipeline company, so targeted licensing or acquisition of adjacent advanced-therapy assets could be a rational longer-term growth path.

The main constraints are also clear: a narrow product portfolio, dependence on U.S. reimbursement, procedural adoption barriers, manufacturing execution risk for autologous products, and competition from lower-cost or more familiar treatment alternatives.

14. What Is the History of Vericel?

• 1989: The company’s roots trace to Aastrom Biosciences, founded in Michigan. Current Vericel materials emphasize the corporate lineage more than a founder-centric story.
• 2014: Aastrom acquired Sanofi’s cell therapy and regenerative medicine business. This was the transformative transaction that brought in Carticel, Epicel, MACI, and the operating infrastructure that shaped the modern company.
• 2015: The company changed its name to Vericel Corporation, signaling a strategic shift toward commercialization of advanced cellular therapies.
• 2016: MACI received FDA approval in the United States, becoming the company’s flagship growth product in sports medicine.
• 2021: Vericel added North American rights to NexoBrid through a licensing agreement with MediWound. Around this period, the legacy Carticel product was also phased out.
• 2022: NexoBrid received FDA approval in the United States for adult thermal-burn eschar removal, broadening Vericel’s burn-care franchise.
• 2025: Vericel announced FDA approval for arthroscopic delivery of MACI, an important commercial and procedural milestone.

15. What Are the Key Suppliers to Vericel?

Suppliers matter strategically for Vericel because its products depend on specialized, validated inputs rather than commodity materials.

• Cell-therapy raw materials. MACI and Epicel require cell-culture media, reagents, sterile disposables, and other cGMP-grade inputs that may not be easy to dual-source quickly.
• Scaffold and biologic-material inputs. MACI depends on a collagen membrane component, making supplier qualification and consistency important.
• Logistics providers. Third-party shipping and handling partners are important because biopsy tissue and finished patient-specific products must move on time and under controlled conditions.
• MediWound. MediWound is especially important as Vericel’s partner and product-source relationship for NexoBrid in North America.

This supplier structure matters because changing a key input or partner in cell therapy can require process validation, operational retraining, and potentially regulatory work.

16. What Are the Key Brands Owned by Vericel?

Branding matters at Vericel, but mostly in a specialist clinical sense rather than a consumer packaged-goods sense. The company’s core brands are its products:

• MACI. Vericel’s flagship brand and the center of its sports-medicine strategy. MACI is positioned as an advanced, restorative cartilage-repair option rather than a simple symptomatic treatment.
• Epicel. A highly specialized severe-burn brand associated with catastrophic-care cases and clinical urgency.
• NexoBrid. A newer burn-care brand that expands Vericel into enzymatic eschar removal and strengthens its relevance within burn-center protocols.

Because Vericel is a focused three-product company, brand architecture is simple. What gives the brands value is clinical trust, evidence, and execution support more than broad consumer advertising.

17. How Does the Supply Chain of Vericel Function?

Vericel’s supply chain is unusually important because two of its products are patient-specific autologous therapies.

1. Biopsy collection and transport. For MACI and Epicel, the process begins at the clinical site, where patient tissue is collected and shipped to Vericel.
2. Manufacturing and quality control. Vericel performs cell expansion and product preparation in a controlled environment, with tight documentation, sterility, and identity controls.
3. Procedure-linked fulfillment. Finished product has to be matched to the patient and delivered in time for a scheduled intervention. That makes demand planning more case-based than forecast-based.
4. Burn-care urgency. Epicel adds urgency because severe burns are often emergent. Supply-chain responsiveness can directly affect clinical usefulness.
5. Partner-supplied product flow for NexoBrid. NexoBrid depends more on partner manufacturing and a specialty-biologics distribution model than on patient-specific manufacturing, but access and inventory still need close coordination with burn centers.

Supply-chain reliability, speed, and exception handling are therefore strategic. A missed shipment, manufacturing delay, or raw-material disruption can have a much larger impact in Vericel’s model than in a standard pill-based pharmaceutical business.

18. What Are the Key Assets of Vericel?

Vericel is not asset-heavy in the way an airline or pipeline operator is, but a relatively small number of assets matter disproportionately.

• Specialized manufacturing facilities and quality systems. These are essential for MACI and Epicel and form a meaningful barrier to entry.
• Regulatory approvals and product rights. MACI, Epicel, and NexoBrid approvals and commercialization rights are core value-bearing assets.
• Clinical know-how and process expertise. In advanced therapies, manufacturing know-how is often as important as formal intellectual property.
• Specialist customer relationships. Surgeon loyalty, burn-center penetration, and treatment-pathway integration are strategic assets even though they do not sit on the balance sheet as physical plant.
• Brand equity in narrow clinical niches. MACI, Epicel, and NexoBrid each carry specialist recognition that can support adoption.

19. What Is the R&D Strategy of Vericel?

Vericel’s R&D strategy appears focused and commercially pragmatic. Public materials suggest the company is not trying to build a broad early-stage discovery engine. Instead, it concentrates R&D spending on lifecycle management, label expansion, clinical evidence generation, and process improvement for products that are already commercial or near commercialization.

The clearest recent example is the MACI arthroscopic administration program, which produced a meaningful regulatory and commercial milestone in 2025. In burn care, Vericel and MediWound have publicly discussed pediatric expansion work for NexoBrid. This kind of R&D profile fits the company’s size and strategy: invest where development spending can directly expand an existing commercial franchise.

That approach can be capital-efficient, but it also means Vericel’s long-term pipeline is less diversified than that of larger biotech companies. The trade-off is intentional: lower scientific sprawl, greater execution focus.

20. What Is the Finance Strategy of Vericel?

Vericel’s finance strategy, as reflected in recent public disclosures, is oriented toward self-funded growth with balance-sheet discipline. The company has emphasized revenue growth, profitability, and cash generation rather than operating as a perpetual cash-burn biotech dependent on large periodic financings.

Capital allocation appears focused on a few priorities: commercial investment behind MACI and the burn franchise, manufacturing and quality infrastructure, targeted clinical development, and selective business-development optionality. Vericel is not positioned like a mature dividend payer. Its financial logic is to reinvest internally generated cash into higher-return growth opportunities while preserving flexibility.

The most important finance-strategy implication is concentration management. Because the portfolio is small and MACI is economically dominant, management has to fund growth without overextending the fixed cost base or taking unnecessary balance-sheet risk.

21. What Major Acquisitions Has Vericel Made?

Vericel has not been a serial acquirer. Its history is shaped by a small number of major portfolio transactions.

• 2014 acquisition of Sanofi’s cell therapy and regenerative medicine business. This was the defining deal in the company’s modern history. It brought the assets and infrastructure that became the basis for MACI, Epicel, and Vericel’s commercial identity.
• 2021 licensing agreement with MediWound for NexoBrid in North America. This was not an acquisition, but it was strategically comparable in importance because it added a new burn-care product and expanded the company’s franchise depth in that market.

The broader pattern is clear: Vericel has preferred focused, strategic portfolio building over continuous M&A. That suggests future deals, if they occur, are more likely to be targeted capability or product additions than large-scale roll-ups.

22. How Companies Like Vericel Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alums of McKinsey, Bain, BCG, and other top consulting firms. Companies like Vericel engage Umbrex when they need talent with the training these top global firms provide, but they do not need a full consulting team with all the overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like Vericel, the best use cases are usually highly targeted projects tied to commercialization, manufacturing, access, and growth execution.

• Build a post-approval growth plan for MACI arthroscopic delivery, including surgeon segmentation, message hierarchy, and account-priority mapping.
• Redesign the MACI patient and referral journey to improve conversion from diagnosis to biopsy to implantation.
• Develop a burn-center account strategy for NexoBrid and Epicel, including formulary sequencing, protocol adoption, and physician-champion plans.
• Optimize reimbursement and patient-access workflows for hospital accounts, prior authorization, and field support.
• Run a manufacturing throughput and scheduling improvement project for autologous therapies, including capacity modeling and exception management.
• Assess supply-chain resilience for single-source raw materials, logistics providers, and partner-supplied product risk.
• Redesign sales territories, incentives, and coverage models across sports medicine and burn care to improve productivity.
• Create a competitive response playbook for treatment alternatives such as microfracture, osteochondral grafting, RECELL, and burn-center substitute protocols.
• Support business development screening for adjacent regenerative-medicine or specialty-hospital assets that fit Vericel’s focused model.
• Design AI-enabled commercial analytics for surgeon targeting, demand forecasting, reimbursement triage, and CRM workflow improvement.